Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.
Blouin M, Han Y, Burch J, Farand J, Mellon C, Gaudreault M, Wrona M, Lévesque JF, Denis D, Mathieu MC, Stocco R, Vigneault E, Therien A, Clark P, Rowland S, Xu D, O'Neill G, Ducharme Y, Friesen R. Blouin M, et al. Among authors: vigneault e. J Med Chem. 2010 Mar 11;53(5):2227-38. doi: 10.1021/jm901771h. J Med Chem. 2010. PMID: 20163116
Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.
Burch JD, Belley M, Fortin R, Deschênes D, Girard M, Colucci J, Farand J, Therien AG, Mathieu MC, Denis D, Vigneault E, Lévesque JF, Gagné S, Wrona M, Xu D, Clark P, Rowland S, Han Y. Burch JD, et al. Among authors: vigneault e. Bioorg Med Chem Lett. 2008 Mar 15;18(6):2048-54. doi: 10.1016/j.bmcl.2008.01.103. Epub 2008 Jan 31. Bioorg Med Chem Lett. 2008. PMID: 18291643
Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor.
Burch JD, Farand J, Colucci J, Sturino C, Ducharme Y, Friesen RW, Lévesque JF, Gagné S, Wrona M, Therien AG, Mathieu MC, Denis D, Vigneault E, Xu D, Clark P, Rowland S, Han Y. Burch JD, et al. Among authors: vigneault e. Bioorg Med Chem Lett. 2011 Feb 1;21(3):1041-6. doi: 10.1016/j.bmcl.2010.12.014. Epub 2010 Dec 8. Bioorg Med Chem Lett. 2011. PMID: 21215624
Erratum.
Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Spratt DE, et al. Among authors: vigneault e. Int J Radiat Oncol Biol Phys. 2024 Sep 23:S0360-3016(24)03323-6. doi: 10.1016/j.ijrobp.2024.08.044. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39320298 Free article. No abstract available.
Striatal projection neurons coexpressing dopamine D1 and D2 receptors modulate the motor function of D1- and D2-SPNs.
Bonnavion P, Varin C, Fakhfouri G, Martinez Olondo P, De Groote A, Cornil A, Lorenzo Lopez R, Pozuelo Fernandez E, Isingrini E, Rainer Q, Xu K, Tzavara E, Vigneault E, Dumas S, de Kerchove d'Exaerde A, Giros B. Bonnavion P, et al. Among authors: vigneault e. Nat Neurosci. 2024 Sep;27(9):1783-1793. doi: 10.1038/s41593-024-01694-4. Epub 2024 Jul 4. Nat Neurosci. 2024. PMID: 38965445
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2405-2415. doi: 10.1016/S0140-6736(24)00548-8. Epub 2024 May 16. Lancet. 2024. PMID: 38763154 Free PMC article. Clinical Trial.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2416-2425. doi: 10.1016/S0140-6736(24)00549-X. Epub 2024 May 16. Lancet. 2024. PMID: 38763153 Free PMC article. Clinical Trial.
Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials.
Nabid A, Carrier N, Vigneault E, Martin AG, Bahary JP, Van Nguyen T, Vavassis P, Vass S, Brassard MA, Bahoric B, Archambault R, Vincent F, Bettahar R, Duclos M, Wilke D, Souhami L. Nabid A, et al. Among authors: vigneault e. Radiother Oncol. 2024 Jun;195:110256. doi: 10.1016/j.radonc.2024.110256. Epub 2024 Mar 27. Radiother Oncol. 2024. PMID: 38552845 Clinical Trial.
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.
Buyyounouski MK, Pugh SL, Chen RC, Mann MJ, Kudchadker RJ, Konski AA, Mian OY, Michalski JM, Vigneault E, Valicenti RK, Barkati M, Lawton CAF, Potters L, Monitto DC, Kittel JA, Schroeder TM, Hannan R, Duncan CE, Rodgers JP, Feng F, Sandler HM. Buyyounouski MK, et al. Among authors: vigneault e. JAMA Oncol. 2024 May 1;10(5):584-591. doi: 10.1001/jamaoncol.2023.7291. JAMA Oncol. 2024. PMID: 38483412 Clinical Trial.
124 results